� Business Monitor International Ltd Page - Pharmaceutical SWOT Analysis - Continued The aggressive expansion of generic drug firms could lead to badly needed foreign investment in domestic manufacturing. The introduction of a mandatory health insurance system in the medium-term will boost demand for innovative therapeutics and all pharmaceuticals Considerable unmet demand for modern treatments will remain for the foreseeable future, creating ongoing opportunities for multinationals to launch new products. ...� Business Monitor International Ltd Page - Pharmaceutical SWOT Analysis - Continued The aggressive expansion of generic drug firms could lead to badly needed foreign investment in domestic manufacturing. The introduction of a mandatory health insurance system in the medium-term will boost demand for innovative therapeutics and all pharmaceuticals Considerable unmet demand for modern treatments will remain for the foreseeable future, creating ongoing opportunities for multinationals to launch new products. WTO accession and new reform agenda has led to the removal of tariffs on pharmaceuticals, lessened regulatory load on multinationals and added opportunities for importers. ...Geopolitical tension with Russia threatens civil stability. Foreign direct investment to remain subdued in relation to other comparable markets, on account of protectionist measures and similar factors.
...In June ----, Gilead Sciences filed a claim against the Ukrainian Drug Regulation Authority and the Ministry of Health alleging a breach of its patents for Sovaldi (sofosbuvir). It is challenging the right for Egyptian generic drugmaker, Pharco Pharmaceuticals, to supply a generic version of the hepatitis C medicine. ...The letter notes the organisation s serious concerns and strong opposition to Gilead s ongoing efforts to remove the only existing source of generic sofosbuvir in Ukraine . In March ----, GlaxoSmithKline altered its patent policy by eschewing its patents in low income countries as well as issuing licences to generic drugmakers for a royalty fee in lower-middle income countries. This is expected to benefit a number of countries, particularly Ukraine where there is currently a patent registered for the firm s HIV drug Tivicay (dolutegravir) and where the country s healthcare system is struggling to treat the large number of HIV-positive patients. ...In March ----, GlaxoSmithKline altered its patent policy by eschewing its patents in low income countries as well as issuing licences to generic drugmakers for a royalty fee in lower-middle income countries. This is expected to benefit a number of countries, particularly Ukraine where there is currently a patent registered for the firm s HIV drug Tivicay (dolutegravir) and where the country s healthcare system is struggling to treat the large number of HIV-positive patients.
...The introduction of a reference pricing mechanism and a simplified medicine registration system bodes well for the outlook of Ukraine s pharmaceutical market. In accordance with a draft bill by the Ministry of Health, which gained approval from Ukrainian parliament on -- May ----, the process of registration for medicines already approved abroad has been simplified. ...
